Impact of influenza vaccine on response to vaccination with pneumococcal vaccine in HIV patients

Roberto Ranieri, A. Veronelli, C. Santambrogio, A. E. Pontiroli

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

The clinical effectiveness of 23-valent pneumococcal vaccine in human immunodeficiency virus (HIV)-infected patients is controversial, because of the low immunological response in these subjects. We studied the clinical response of pneumococcal vaccine and the relative impact of influenza vaccine by administering both pneumococcal and influenza vaccine in a group of 150 HIV patients belonging to all CDC categories. In the group of 90 HIV-infected patients vaccinated against both pneumonia and influenza virus, there was a low incidence of mild influenza (13.3%) and no case of pneumococcal pneumonia. On the contrary, among 60 nonvaccinated HIV patients, 61.6% underwent mild to severe influenza and two developed pneumococcal pneumonia. 23-valent pneumococcal vaccine (PV) seems to be clinically effective in preventing pneumonia in HIV-infected patients, and even more if strengthened by influenza vaccine.

Original languageEnglish
Pages (from-to)407-409
Number of pages3
JournalAIDS Research and Human Retroviruses
Volume21
Issue number5
DOIs
Publication statusPublished - May 2005

Fingerprint

Pneumococcal Vaccines
Influenza Vaccines
Vaccination
HIV
Pneumococcal Pneumonia
Human Influenza
Pneumonia
Centers for Disease Control and Prevention (U.S.)
Orthomyxoviridae
Incidence

ASJC Scopus subject areas

  • Immunology
  • Virology

Cite this

Impact of influenza vaccine on response to vaccination with pneumococcal vaccine in HIV patients. / Ranieri, Roberto; Veronelli, A.; Santambrogio, C.; Pontiroli, A. E.

In: AIDS Research and Human Retroviruses, Vol. 21, No. 5, 05.2005, p. 407-409.

Research output: Contribution to journalArticle

@article{5e6df24c8bc649c3a7fecc9f3782e84f,
title = "Impact of influenza vaccine on response to vaccination with pneumococcal vaccine in HIV patients",
abstract = "The clinical effectiveness of 23-valent pneumococcal vaccine in human immunodeficiency virus (HIV)-infected patients is controversial, because of the low immunological response in these subjects. We studied the clinical response of pneumococcal vaccine and the relative impact of influenza vaccine by administering both pneumococcal and influenza vaccine in a group of 150 HIV patients belonging to all CDC categories. In the group of 90 HIV-infected patients vaccinated against both pneumonia and influenza virus, there was a low incidence of mild influenza (13.3{\%}) and no case of pneumococcal pneumonia. On the contrary, among 60 nonvaccinated HIV patients, 61.6{\%} underwent mild to severe influenza and two developed pneumococcal pneumonia. 23-valent pneumococcal vaccine (PV) seems to be clinically effective in preventing pneumonia in HIV-infected patients, and even more if strengthened by influenza vaccine.",
author = "Roberto Ranieri and A. Veronelli and C. Santambrogio and Pontiroli, {A. E.}",
year = "2005",
month = "5",
doi = "10.1089/aid.2005.21.407",
language = "English",
volume = "21",
pages = "407--409",
journal = "AIDS Research and Human Retroviruses",
issn = "0889-2229",
publisher = "Mary Ann Liebert Inc.",
number = "5",

}

TY - JOUR

T1 - Impact of influenza vaccine on response to vaccination with pneumococcal vaccine in HIV patients

AU - Ranieri, Roberto

AU - Veronelli, A.

AU - Santambrogio, C.

AU - Pontiroli, A. E.

PY - 2005/5

Y1 - 2005/5

N2 - The clinical effectiveness of 23-valent pneumococcal vaccine in human immunodeficiency virus (HIV)-infected patients is controversial, because of the low immunological response in these subjects. We studied the clinical response of pneumococcal vaccine and the relative impact of influenza vaccine by administering both pneumococcal and influenza vaccine in a group of 150 HIV patients belonging to all CDC categories. In the group of 90 HIV-infected patients vaccinated against both pneumonia and influenza virus, there was a low incidence of mild influenza (13.3%) and no case of pneumococcal pneumonia. On the contrary, among 60 nonvaccinated HIV patients, 61.6% underwent mild to severe influenza and two developed pneumococcal pneumonia. 23-valent pneumococcal vaccine (PV) seems to be clinically effective in preventing pneumonia in HIV-infected patients, and even more if strengthened by influenza vaccine.

AB - The clinical effectiveness of 23-valent pneumococcal vaccine in human immunodeficiency virus (HIV)-infected patients is controversial, because of the low immunological response in these subjects. We studied the clinical response of pneumococcal vaccine and the relative impact of influenza vaccine by administering both pneumococcal and influenza vaccine in a group of 150 HIV patients belonging to all CDC categories. In the group of 90 HIV-infected patients vaccinated against both pneumonia and influenza virus, there was a low incidence of mild influenza (13.3%) and no case of pneumococcal pneumonia. On the contrary, among 60 nonvaccinated HIV patients, 61.6% underwent mild to severe influenza and two developed pneumococcal pneumonia. 23-valent pneumococcal vaccine (PV) seems to be clinically effective in preventing pneumonia in HIV-infected patients, and even more if strengthened by influenza vaccine.

UR - http://www.scopus.com/inward/record.url?scp=20444368775&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=20444368775&partnerID=8YFLogxK

U2 - 10.1089/aid.2005.21.407

DO - 10.1089/aid.2005.21.407

M3 - Article

C2 - 15929703

AN - SCOPUS:20444368775

VL - 21

SP - 407

EP - 409

JO - AIDS Research and Human Retroviruses

JF - AIDS Research and Human Retroviruses

SN - 0889-2229

IS - 5

ER -